Monte Rosa Therapeutics, Inc.
GLUENASDAQHealthcare● Active
$17.00
+$0.63(+3.85%)
Market Cap$1.1B
P/E Ratio—
52W High$25.77
52W Low$4.12
Monte Rosa Therapeutics, Inc. (GLUE) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GLUE · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.12B | $0.08B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Gross Profit | $0.12B | $0.07B | ($0.01B) | $0.00B | $0.00B |
| Gross Margin %(computed) | 93.24% | 89.26% | — | — | — |
| Operating Expenses | |||||
| R&D Expenses | $0.14B | $0.12B | $0.11B | $0.09B | $0.06B |
| G&A Expenses | $0.04B | $0.04B | $0.03B | $0.03B | $0.02B |
| Total Operating Expenses | $0.17B | $0.15B | $0.14B | $0.11B | $0.07B |
| Operating Income | ($0.05B) | ($0.08B) | ($0.14B) | ($0.11B) | ($0.07B) |
| Operating Margin %(computed) | -43.83% | -107.26% | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.04B) | ($0.07B) | ($0.14B) | ($0.11B) | ($0.07B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.04B) | ($0.07B) | ($0.14B) | ($0.11B) | ($0.07B) |
| Net Margin %(computed) | -31.23% | -96.14% | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.46 | $-0.98 | $-2.63 | $-2.30 | $-1.59 |
| Wtd Avg Shares | 0.08B | 0.07B | 0.05B | 0.05B | 0.05B |
| EBITDA | ($0.05B) | ($0.07B) | ($0.14B) | ($0.11B) | ($0.07B) |
| EBITDA Margin %(computed) | -37.08% | -96.52% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Monte Rosa Therapeutics, Inc. data
About Monte Rosa Therapeutics, Inc. (GLUE) Income Statement
Monte Rosa Therapeutics, Inc. (GLUE) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GLUE reported revenue of $0.12B, gross profit of $0.12B (gross margin 93.24%), and net income of ($0.04B) — a net profit margin of -31.23%.
Frequently asked questions
GLUE · 4 questionsMonte Rosa Therapeutics, Inc. (GLUE) reported revenue of $0.12B for 2025, up 63.5% year-over-year.
GLUE revenueGLUE salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08